©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2024; 16(4): 511-516
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.511
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.511
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
Arghya Samanta, Moinak Sen Sarma, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
Author contributions: Samanta A did the literature review and wrote the original manuscript; Sen Sarma M reviewed and revised the manuscript, did critical analysis; All authors approved the final draft of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Corresponding author: Moinak Sen Sarma, MBBS, MD, Adjunct Associate Professor, Doctor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India. moinaksen@yahoo.com
Received: January 23, 2024
Revised: March 5, 2024
Accepted: April 7, 2024
Published online: April 27, 2024
Processing time: 91 Days and 20.4 Hours
Revised: March 5, 2024
Accepted: April 7, 2024
Published online: April 27, 2024
Processing time: 91 Days and 20.4 Hours
Core Tip
Core Tip: Non-alcoholic fatty liver disease is often considered the hepatic manifestation of metabolic syndrome. The new nomenclature of “metabolic dysfunction associated steatotic liver disease” emphasizes the role of disordered metabolism in the pathogenesis. Weight reduction by lifestyle changes is the mainstay of treatment.